Influence of tamoxifen on ocular morphology and function
Abstract
Background: Tamoxifen, a commonly used selective estrogen receptor antagonist for adjuvant therapy in hormone receptor-positive breast cancer, can cause ocular side effects due to estrogen receptors in ocular structures. This prospective study explores its impact on ocular morphology and function.
Materials and methods: This prospective, non-interventional, cross-sectional study explores the effects of tamoxifen on ocular morphology, visual acuity, and quality. Examinations included objective refractometry, visual acuity, contrast sensitivity, color vision, visual field tests, corneal topography, optical coherence tomography, autofluorescence, and slit lamp biomicroscopy. Participants completed a health questionnaire. Statistical analysis, using linear or logistic (mixed) regression, compared tamoxifen's effects to a control group.
Results: A total of 102 patients were included: 90 in the study group and 12 controls. The duration of tamoxifen therapy showed a clinically relevant impact on the visual field, with a mean loss variance change of 0.045 dB² per week (95% CI [0.012 dB²; 0.079 dB²]). Corneal thickness decreased by -0.12 μm per week (95% CI [-0.20 μm; -0.031 μm]) with longer therapy duration. Fourteen patients received additional aromatase inhibitors, and this group showed clinically significant reductions in both visual acuity and contrast vision. No correlation was observed between tamoxifen intake and visual acuity, contrast vision, color vision, mean defect in…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 102 participants or records.
Read the paper
Related studies
- A Coupled SYSTEM of Intracellular Ca 2+ Clocks and Surface Membrane Voltage Clocks Controls the Timekeeping Mechanism of the Heart’s Pacemaker
- A Comprehensive Review on the Therapeutic Potential of Curcuma longa Linn. in Relation to its Major Active Constituent Curcumin
- Cancer epigenetics: Moving forward
- Current developments in LC-MS for pharmaceutical analysis
- Myricetin: A comprehensive review on its biological potentials
- A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.